Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Prohibited at all times
2026 S4.4.1: prohibited at all times. Non-Specified. [1]
S4.4.1 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Identity and evidence quality
FDA’s July 2026 assessment describes MOTS-c as a 16-amino-acid mitochondrial-derived peptide. It identified uncertainty about material identity, aggregation, impurities and possible immunogenicity, and did not find adequate administered-human evidence to assess the proposed native MOTS-c products. This was a dated scientific assessment, not proof that no later evidence can exist. [2]
- Endogenous peptide biology and measurements of natural peptide levels are not trials of injected products.
Changing compounding policy
The later HHS interim policy includes conditional enforcement discretion for specified MOTS-c acetate preparations, subject to identity, route and quality requirements. It cites additional characterization and analogue evidence. The policy explicitly distinguishes compounded drugs from FDA-approved drugs; it does not establish clinical benefit or anti-doping permission. [3]
- Analogue and animal findings cannot simply be transferred to native MOTS-c. This page is not a guide to lawful compounding, prescribing or use.
What remains uncertain
- Current implementation of the interim policy, subsequent data and country-specific legal status require specialist verification before a real treatment or compliance decision.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · Relevant official full-text sections opened
Printed pp. 3, 9–12: introduction, S3, S4 and S5 as applicable
- FDA PCAC presentation: MOTS-c free base and acetate ↗Accessed 2026-11-10 · Relevant document text opened
PDF pp. 120–149, MOTS-c assessment; especially identity, effectiveness and safety
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances ↗Accessed 2026-11-10 · Relevant document text opened
pp. 1–3 and MOTS-c appendix pp. 9–10
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.